Efficacy and Safety of Benazepril for Advanced Chronic Renal Insufficiency
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Angiotensin-converting-enzyme inhibitors provide renal protection in patients with mild-to-moderate renal insufficiency (serum creatinine level, 3.0 mg per deciliter or less). We assessed the efficacy and safety of benazepril in patients without diabetes who had advanced renal insufficiency. METHODS: We enrolled 422 patients in a randomized, double-blind study. After an eight-week run-in period, 104 patients with serum creatinine levels of 1.5 to 3.0 mg per deciliter (group 1) received 20 mg of benazepril per day, whereas 224 patients with serum creatinine levels of 3.1 to 5.0 mg per deciliter (group 2) were randomly assigned to receive 20 mg of benazepril per day (112 patients) or placebo (112 patients) and then followed for a mean of 3.4 years. All patients received conventional antihypertensive therapy. The primary outcome was the composite of a doubling of the serum creatinine level, end-stage renal disease, or death. Secondary end points included changes in the level of proteinuria and the rate of progression of renal disease. RESULTS: Of 102 patients in group 1, 22 (22 percent) reached the primary end point, as compared with 44 of 108 patients given benazepril in group 2 (41 percent) and 65 of 107 patients given placebo in group 2 (60 percent). As compared with placebo, benazepril was associated with a 43 percent reduction in the risk of the primary end point in group 2 (P=0.005). This benefit did not appear to be attributable to blood-pressure control. Benazepril therapy was associated with a 52 percent reduction in the level of proteinuria and a reduction of 23 percent in the rate of decline in renal function. The overall incidence of major adverse events in the benazepril and placebo subgroups of group 2 was similar. CONCLUSIONS: Benazepril conferred substantial renal benefits in patients without diabetes who had advanced renal insufficiency. (ClinicalTrials.gov number, NCT00270426.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Our trial confirms that the kidneyprotective effects of SGLT2 inhibitors extend to the broader population of persons with chronic kidney disease without type 2 diabetes, for whom ACE inhibitors are the only pharmacologic treatments that have been shown to prevent kidney failure.3,4”
From Dapagliflozin in Patients with Chronic Kidney Disease (2020) · cites this paper as [4]
Citations
Cites
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Maschio, G., Alberti, D., Janin, G., Locatelli, F., Mann, J. F. E., Motolese, M., Ponticelli, C., Ritz, E., & Zucchelli, P. (1996) · New England Journal of Medicine · doi:10.1056/nejm199604113341502 · Cited by 1,766
(2000) · Journal of the American Society of Nephrology · Cited by 1,718
Peterson, J. C., Adler, S., Burkart, J. M., Greene, T., Hebert, L. A., Hunsicker, L. G., King, A. J., Klahr, S., Massry, S. G., Seifter, J. L., et al. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-123-10-199511150-00003 · Cited by 1,342
Bakris, G. L., & Weir, M. R. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.5.685 · Cited by 823
Coresh, J., Astor, B. C., McQuillan, G., Kusek, J., Greene, T., Van Lente, F., & Levey, A. S. (2002) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2002.32765 · Cited by 717
A SIMPLE METHOD OF ESTIMATING PROGRESSION OF CHRONIC RENAL FAILURE
Mitch, W. E., Walser, M., Buffington, G. A., & Lemann, J. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91974-7 · Cited by 459
Ruggenenti, P., Nefrologia”(GISEN), O. B. O. T. “. I. D. S. E. I., Perna, A., Mosconi, L., Pisoni, R., & Remuzzi, G. (1998) · Kidney International · doi:10.1046/j.1523-1755.1998.00874.x · Cited by 434
Research works printed but not linked: 4
- 2001, Chin J Nephrol, 17, 77
- Hou FF, 2005, Zhonghua Yi Xue Za Zhi, 85, 458
- Zhang GH, 2005, Zhonghua Nei Ke Za Zhi, 44, 592
- Levey AS, 2000, J Am Soc Nephrol, 11, 155A
Cited by
Items 201–300 of 702
Gregorini, M., Corradetti, V., Rocca, C., Pattonieri, E. F., Valsania, T., Milanesi, S., Serpieri, N., Bedino, G., Esposito, P. B., Libetta, C., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0148542 · Cited by 34
Krairittichai, U., Mahannopkul, R., & Bunnag, S. (2012) · PubMed · Cited by 34
Highly Enantioselective Hydrogenation of β-Ketoenamides with the Rh-ZhangPhos Catalyst
Huang, K., Zhang, X., Geng, H., Li, S.-K., & Zhang, X. (2012) · ACS Catalysis · doi:10.1021/cs300037z · Cited by 34
Self-citationTanaka, K., Saito, H., Iwasaki, T., Oda, A., Watanabe, S., Kanno, M., Kimura, H., Shimabukuro, M., Asahi, K., Watanabe, T., et al. (2021) · Clinical and Experimental Nephrology · doi:10.1007/s10157-020-02010-7 · Cited by 33
[4+3]-Cycloaddition Reaction of Sulfilimines with Cyclobutenones: Access to Benzazepinones
Xie, X., & Sun, J. (2021) · Organic Letters · doi:10.1021/acs.orglett.1c03413 · Cited by 33
Taal, M. W., Lucas, B. J., Roderick, P. J., Cockwell, P., Wheeler, D. C., Saleem, M. A., Fraser, S. D., Banks, R. E., Johnson, T. S., Hale, L. J., et al. (2023) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfad110 · Cited by 40
Oh, Y. J., Kim, S. M., Shin, B. C., Kim, H. L., Chung, J. H., Kim, A. J., Ro, H., Chang, J. H., Lee, H. H., Chung, W., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0170874 · Cited by 37
Xiong, C., Li, L., Wang, B., Chen, H., XiaoWei, L., Hongbao, L., & Zhang, P. (2019) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2019.11.001 · Cited by 33
Role of renin-angiotensin system blockade in advanced CKD: to use or not to use?
Mukoyama, M., & Kuwabara, T. (2022) · Hypertension Research · doi:10.1038/s41440-022-00902-7 · Cited by 33
Kidney Dysfunction and Left Ventricular Assist Device Support: A Comprehensive Perioperative Review
Coffin, S. T., Waguespack, D. R., Haglund, N. A., Maltais, S., Dwyer, J. P., & Keebler, M. (2015) · Cardiorenal Medicine · doi:10.1159/000369589 · Cited by 35
Ma, T.-C., Yao, S., Qiao, M., Yuan, F., Shi, D., & Xiao, W. (2021) · Organic Chemistry Frontiers · doi:10.1039/d1qo00543j · Cited by 32
Chen, M., Chen, Y., Sun, N., Zhao, J., Liu, Y., & Li, Y. (2014) · Angewandte Chemie · doi:10.1002/ange.201410056 · Cited by 32
Jun, M., Lv, J., Perkovic, V., & Jardine, M. (2011) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622311401775 · Cited by 39
“…et al. 2001] or without diabetes (Angiotensin-Converting Enzyme Inhibition in Progressive Renal Insufficiency study (AIPRI), Ramipril Efficacy in Nephropathy study (REIN)) [Jafar et al. 2003; GISEN Group, 1997; Maschio et al. 1996], or advanced CKD (SCr > 3 mg/dl) [Hou et al. 2006].”
BackgroundEsnault, V. L. M., Ekhlas, A., Nguyen, J., & Moranne, O. P. (2010) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp776 · Cited by 36
“Treatment of both high blood pressure and proteinuria over 0.5 g/day is required to control the progression of chronic kidney disease (CKD) [1,2].”
BackgroundInfluentialSuramin Alleviates Glomerular Injury and Inflammation in the Remnant Kidney
Liu, N., He, S., Tolbert, E. M., Gong, R., Bayliss, G. P., & Zhuang, S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036194 · Cited by 32
“Although therapeutic interventions such as the blockade of the renninangiotensin-aldosterone system and immunosuppressive drugs slow the progression of renal disease and promote renoprotective effects in experimental animal models [1,2] and in humans [3,4], these strategies cannot halt the progression of renal fibrosi…”
BackgroundMACGREGOR, M. S., & Taal, M. W. (2011) · Nephron Clinical Practice · doi:10.1159/000328062 · Cited by 34
Renin-Angiotensin System Blockade in Advanced Kidney Disease: Stop or Continue?
Burnier, M. (2020) · Kidney Medicine · doi:10.1016/j.xkme.2020.04.002 · Cited by 33
Loutradis, C., Price, A. M., Ferro, C. J., & Sarafidis, P. A. (2021) · Journal of Human Hypertension · doi:10.1038/s41371-021-00504-9 · Cited by 34
Maddirala, S., Khan, A., Vincent, A. S., & Lau, K. (2008) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e3181836ac7 · Cited by 36
Chen, P.-M., Lai, T., Chen, P., Lai, C., Wu, V., Chiang, W., Chen, Y., Wu, K., & Tsai, T. (2014) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2014.01.002 · Cited by 31
Self-citationNaritomi, H., Fujita, T., Ito, S., Ogihara, T., Shimada, K., Shimamoto, K., Tanaka, H., & Yoshiike, N. (2008) · Hypertension Research · doi:10.1291/hypres.31.295 · Cited by 39
Cheng, H., & Harris, R. C. (2006) · Expert Opinion on Drug Safety · doi:10.1517/14740338.5.5.631 · Cited by 32
Niu, B., Nie, Q., Huang, B., & Cai, M. (2019) · Advanced Synthesis & Catalysis · doi:10.1002/adsc.201900512 · Cited by 31
Li, D., Park, Y., Yoon, W., Yun, H., & Yun, J. (2019) · Organic Letters · doi:10.1021/acs.orglett.9b03853 · Cited by 31
Toto, R. D., & Palmer, B. F. (2007) · American Journal of Nephrology · doi:10.1159/000112269 · Cited by 31
“several studies demonstrate that both classes of agents have specific renoprotective effects beyond those resulting from lowering blood pressure [ , , , , , ,”
BackgroundElevations in serum creatinine with RAAS blockade: why isnʼt it a sign of kidney injury?
Ryan, M. J., & Tuttle, K. R. (2008) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e32830a9606 · Cited by 35
Association of Albuminuria Levels With the Prescription of Renin-Angiotensin System Blockade
Qiao, Y., Shin, J., Chen, T. K., Sang, Y., Coresh, J., Vassalotti, J. A., Chang, A. R., & Grams, M. E. (2020) · Hypertension · doi:10.1161/hypertensionaha.120.15956 · Cited by 31
Mao, W., Yang, N., Zhang, L., Li, C., Wu, Y., Ouyang, W., Xu, P. H., Zou, C., Pei, C., Shi, W., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.627185 · Cited by 35
Zhang, X.-Y., Wu, X., Zhang, B., Wei, Y., & Shi, M. J. (2021) · ACS Catalysis · doi:10.1021/acscatal.1c00240 · Cited by 30
Self-citationHu, Y., Liang, L., Liu, S., Kung, J. Y. C., & Banh, H. L. (2023) · Journal of Clinical Hypertension · doi:10.1111/jch.14695 · Cited by 38
Abraham, A. G., Betoko, A. S., Fadrowski, J. J., Pierce, C. B., Furth, S. L., Warady, B. A., & Muñoz, Á. (2016) · Pediatric Nephrology · doi:10.1007/s00467-016-3512-4 · Cited by 30
“adult studies have reported effect sizes within the range 40– 70 % for ESRD and serum creatinine doubling endpoints [2, 3, 26, 27].”
Kefale, B., Tadesse, Y., Woldu, M. A., & Engidawork, E. (2018) · PLoS ONE · doi:10.1371/journal.pone.0200415 · Cited by 34
RetractedRisk-directed management of chronic kidney disease
Blum, M. F., Neuen, B. L., & Grams, M. E. (2025) · Nature Reviews Nephrology · doi:10.1038/s41581-025-00931-8 · Cited by 39
Diabetic Cardiovascular Disease: Getting to the Heart of the Matter
Peterson, L. R., McKenzie, C. R., & Schaffer, J. E. (2012) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-012-9374-7 · Cited by 33
When should we start and stop ACEi/ARB in paediatric chronic kidney disease?
Chan, E. Y.-H., Ma, A. L.-T., & Tullus, K. (2020) · Pediatric Nephrology · doi:10.1007/s00467-020-04788-w · Cited by 30
Li, L., Lai, E. Y., Luo, Z., Solis, G., Mendonca, M., Griendling, K. K., Wellstein, A., Welch, W. J., & Wilcox, C. S. (2018) · Hypertension · doi:10.1161/hypertensionaha.118.11354 · Cited by 29
Zhang, X., Ning, C., Long, Y.-J., Wei, Y., & Shi, M. J. (2020) · Organic Letters · doi:10.1021/acs.orglett.0c01856 · Cited by 28
Self-citationLi, Q., Jia, Z.-Q., Chen, L., Zhang, X., Leng, H., Zeng, R., Liu, Y., Zou, W., & Li, J. (2021) · Organic Letters · doi:10.1021/acs.orglett.0c04041 · Cited by 28
Self-citationMishina, M., & Watanabe, T. (2008) · Journal of Veterinary Medical Science · doi:10.1292/jvms.70.455 · Cited by 32
“Since the advent of ACE inhibitors, various types of ACE inhibitor have been developed and, along with ANG receptor blockers, have become mainstay conservative treatments for chronic renal failure in humans [8, 18, 35, 42].”
BackgroundClinical Manifestations and Natural History of Diabetic Kidney Disease
Ritz, E. (2013) · Medical Clinics of North America · doi:10.1016/j.mcna.2012.10.008 · Cited by 29
Shen, J. I., Saxena, A. B., Montez‐Rath, M. E., Chang, T. I., & Winkelmayer, W. C. (2016) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfw053 · Cited by 31
Renal dysfunction in heart failure patients: what is the evidence?
SALTZMAN, H. E., Sharma, K., Mather, P. J., Rubin, S., Adams, S., & Whellan, D. J. (2007) · Heart Failure Reviews · doi:10.1007/s10741-007-9006-5 · Cited by 28
“[91] showed that the ACE-inhibitor benazapril conferred significant protection to patients with advanced renal insufficiency.”
BackgroundHattori, K., Sakaguchi, Y., Oka, T., Asahina, Y., Kawaoka, T., Doi, Y., Hashimoto, N., Kusunoki, Y., Yamamoto, S., Yamato, M., et al. (2024) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000000000425 · Cited by 27
The Cardiorenal Syndrome: What the Cardiologist Needs to Know
Waldum, B., & Os, I. (2013) · Cardiology · doi:10.1159/000353261 · Cited by 31
Jiang, B., Liu, J.-X., Wei, Y., & Shi, M. J. (2018) · Organic Letters · doi:10.1021/acs.orglett.8b02699 · Cited by 27
Zhou, N., Zhao, F., Wang, L., Gao, X., Zhao, X., & Zhang, M. (2023) · Organic Letters · doi:10.1021/acs.orglett.3c02323 · Cited by 27
Natural history of CKD stage 4 and 5 patients following referral to renal management clinic
Zhang, A., Tam, P. Y., LeBlanc, D., Zhong, H., Chan, C. T., Bargman, J. M., & Oreopoulos, D. G. (2009) · International Urology and Nephrology · doi:10.1007/s11255-009-9604-3 · Cited by 27
“Some previous studies have suggested that the use of ACE inhibitors/ARBs could protect renal function in stage 4 even stage 5 patients [13–15].”
MethodArora, N., Katz, R., & Bansal, N. (2020) · Kidney Medicine · doi:10.1016/j.xkme.2019.12.007 · Cited by 30
“However, we did not find differences in risk for progression to ESRD or mortality based on patterns of RAS inhibitor use during advanced stages of CKD. Investigation of therapies to improve clinical outcomes in this vulnerable and high-risk period should be prioritized.”
BackgroundInfluentialLi, Y., Miao, R.-P., Liu, Y., Zhang, J., Dou, Z., Zhao, L., Zhang, Y., Huang, Z., Ye, X., & Han, D. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.656621 · Cited by 35
“Furthermore, ARB/ACE inhibitors can induce fatal side-effects in patients with advanced stages of chronic renal insufficiency and having a serum creatinine level greater than 3mg/dL (7).”
BackgroundAdarkwah, C. C., Gandjour, A., Akkerman, M. K., & Evers, S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026139 · Cited by 31
“Diabetic nephropathy may progress to ESRD, which is defined by the need for either long-term dialysis or renal transplantation [8].”
BackgroundEffects of angiotensin II receptor blockers on diabetic nephropathy
Kalaitzidis, R., & Bakris, G. L. (2009) · Journal of Hypertension · doi:10.1097/01.hjh.0000357904.71080.7d · Cited by 28
Yamamoto, D., Takai, S., Hirahara, I., & Kusano, E. (2010) · Clinica Chimica Acta · doi:10.1016/j.cca.2010.02.059 · Cited by 27
“Angiotensin-converting enzyme (ACE) inhibitors have been shown to have protective effects in patients with renal failure and to improve survival [9,10].”
BackgroundJennings, D. L., & Taber, D. J. (2007) · Annals of Pharmacotherapy · doi:10.1345/aph.1k471 · Cited by 26
Espinel, E., Joven, J., Nuñez-Gil, I. J., Suñé, P., Renedo, B., Fort, J., & Serón, D. (2013) · BMC Research Notes · doi:10.1186/1756-0500-6-306 · Cited by 26
Palladium-Catalyzed Ring Expansion of Spirocyclopropanes to Form Caprolactams and Azepanes
René, O., Stepek, I. A., Gobbi, A., Fauber, B. P., & Gaines, S. (2015) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.5b01846 · Cited by 26
Stoycheff, N., Pandya, K. A., Okparavero, A., Schiff, A. E., Levey, A. S., Greene, T., & Stevens, L. A. (2010) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfq525 · Cited by 26
“Hou 2006 [26] 422 Non-diabetic (various) Benazapril 24-h P Placebo ●”
MethodKalaitzidis, R., & Bakris, G. L. (2009) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e32832edc99 · Cited by 27
Karuppasamy, M., Vachan, B. S., Vinoth, P., Muthukrishnan, I., Nagarajan, S., Ielo, L., Pace, V., Banik, S., Maheswari, C. U., & Sridharan, V. (2019) · Organic Letters · doi:10.1021/acs.orglett.9b01482 · Cited by 25
Discontinuation of RAAS Inhibition in Children with Advanced CKD
van den Belt, S. M., Heerspink, H. J. L., Kirchner, M., Gracchi, V., Thurn‐Valsassina, D., Bayazıt, A. K., Niemirska, A., Canpolat, N., Bulut, İ. K., Ažukaitis, K., et al. (2020) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.09750819 · Cited by 25
Ku, E., Tighiouart, H., McCulloch, C. E., Inker, L. A., Adingwupu, O. M., Greene, T., Estacio, R. O., Woodward, M., de Zeeuw, D., Lewis, J. B., et al. (2024) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000000000426 · Cited by 24
Self-citationChiang, C., Hung, C., Wu, Y., Lin, T., Ueng, K., Sung, S., Wu, C., Chao, T., Lin, H., Lin, Y., et al. (2023) · PubMed Central · doi:10.6515/acs.202305_39(3).20230301a · Cited by 30
for the Combination Therapy of Hypertension to Prevent Cardiovascular Events Trial Group, Rakugi, H., Ogihara, T., Umemoto, S., Matsuzaki, M., Matsuoka, H., Shimada, K., Higaki, J., Ito, S., Kamiya, A., et al. (2013) · Hypertension Research · doi:10.1038/hr.2013.63 · Cited by 27
Refining Kidney Survival in 383 Genetically Characterized Patients With Nephronophthisis
König, J. C., Karsay, R., Gerß, J., Schlingmann, K., Dahmer‐Heath, M., Telgmann, A.-K., Kollmann, S., Ariceta, G., Gillion, V., Böckenhauer, D., et al. (2022) · Kidney International Reports · doi:10.1016/j.ekir.2022.05.035 · Cited by 29
“The association of ACEIswith a negative effect on kidney survival observed in our study appeared peculiar at first glance considering the nephroprotective benefits of ACEI treatment in the setting of chronic kidneydisease.(56,57)However, a detailed look at the original pediatric data reveals that these benefits were m…”
BackgroundMohan, A., Majd, Z., Johnson, M. L., Essien, E. J., Barner, J. C., Serna, O., Gallardo, E., Fleming, M. L., Ordonez, N. D., Holstad, M. M., et al. (2023) · Drugs & Aging · doi:10.1007/s40266-023-01008-6 · Cited by 30
“Due to the reno-protective effect of ACEIs/ARBs, they are recommended as the first-line medication among elderly patients with comorbid diabetes and hypertension [44, 45].”
BackgroundInhibition of the renin–angiotensin system and chronic kidney disease
Siamopoulos, K. C., & Kalaitzidis, R. (2008) · International Urology and Nephrology · doi:10.1007/s11255-008-9424-x · Cited by 26
“Benazepril therapy was associated with a 52% reduction in the level of proteinuria and a reduction of 23% in the rate of decline in renal function and conferred substantial renal benefits in patients without diabetes who had advanced renal insufficiency [43].”
BackgroundResistant Hypertension and Chronic Kidney Disease: a Dangerous Liaison
Wolley, M. J., & Stowasser, M. (2016) · Current Hypertension Reports · doi:10.1007/s11906-016-0641-x · Cited by 25
Chen, C., Wu, H., Wang, C.-L., Yang, F., Wu, P., Hung, S., Kan, W., Yang, C., Chiang, C., Huang, J., et al. (2016) · Scientific Reports · doi:10.1038/srep26539 · Cited by 30
Optimizing ACE-Inhibitor Therapy for Chronic Kidney Disease
Hebert, L. A. (2006) · New England Journal of Medicine · doi:10.1056/nejme058295 · Cited by 24
Rump, L. C. (2006) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfl549 · Cited by 25
Niu, H., Nie, L., Liu, M., Chi, Y., Zhang, T., & Li, Y. (2014) · BMC Nephrology · doi:10.1186/1471-2369-15-135 · Cited by 23
“preventing renal and retinal complications of diabetes [35].”
BackgroundDriver, T. G., & Mazumdar, W. (2021) · Synthesis · doi:10.1055/s-0040-1705995 · Cited by 23
Characterizing pre-dialysis care in the era of eGFR reporting: a cohort study
Abdel-Kader, K. F. M., Fischer, G. S., Johnston, J. R., Gu, C., Moore, C. G., & Unruh, M. L. (2011) · BMC Nephrology · doi:10.1186/1471-2369-12-12 · Cited by 23
“While a trend towards improved ACEI/ARB use was seen in co-managed CKD stage 4 patients, we suspect this was due to recent literature documenting the safety and efficacy of ACEI treatment in the setting of advanced CKD that was not available during the pre-eGFR cohort [43].”
Locatelli, F., Vecchio, L. D., & Cavalli, A. (2009) · Nephron Clinical Practice · doi:10.1159/000235946 · Cited by 24
Outcomes of KDIGO-Defined CKD in U.S. Veterans With HFpEF, HFmrEF, and HFrEF
Patel, S. D., Raman, V. K., Faselis, C. J., Fonarow, G. C., Lam, P. H., Ahmed, A. A., Heidenreich, P. A., Anker, S. D., DEEDWANIA, P. C., Morgan, C. J., et al. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2024.11.007 · Cited by 26
Damman, K., ter Maaten, J. M., Mayne, K. J., Bolignano, D., Brown, E. M., da Costa, B. R., Dagre, A. G., Gansevoort, R. T., Gavina, C., Goette, A., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag098 · Cited by 33
Zhou, T., Yin, S.-S., & Liang, R. (2012) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320312459978 · Cited by 22
Burnier, M., Lin, S., Ruilope, L. M., Bader, G., Durg, S., & Brunel, P. (2019) · Blood Pressure · doi:10.1080/08037051.2019.1644155 · Cited by 26
“Even in patients with advanced CKD, ARB and ACEIs are effective in delaying the disease progression [28,29].”
BackgroundMineralcorticoid receptor blockers in chronic kidney disease
Erraez, S., López-Mesa, M., & Gómez-Fernández, P. (2021) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2021.08.001 · Cited by 21
Coronado-Cáceres, L. J., Hernández‐Ledesma, B., Mojica, L., Quevedo-Corona, L., Rabadán-Chávez, G. M., Castillo-Herrera, G. A., & Lugo‐Cervantes, E. (2021) · Foods · doi:10.3390/foods10102340 · Cited by 22
Lattanzio, M. R., & Weir, M. R. (2010) · Current Hypertension Reports · doi:10.1007/s11906-010-0142-2 · Cited by 26
“Benazepril therapy was associated with a 52% reduction in the level of proteinuria and a 23% reduction in the rate of decline in renal function [ 23 ].”
BackgroundMethodInfluentialKhan, Y. H., Sarriff, A., Adnan, A. S., Khan, A. H., Mallhi, T. H., & Jummaat, F. B. (2015) · Nephrology · doi:10.1111/nep.12713 · Cited by 22
“These results are comparable to studies conducted in Chinese and Taiwanese population.(27,28) At the end of follow-up, approximately 22% study subjects maintained or even improved their baseline CKD stage.”
Hypertension and Kidney Damage
Griffin, K. A., & BIDANI, A. K. (2006) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2005.05111.x · Cited by 24
Moriyama, T., Tsuruta, Y., Kojima, C., Itabashi, M., Sugiura, H., Takei, T., Ogawa, T., Uchida, K., Tsuchiya, K., & Nitta, K. (2011) · International Urology and Nephrology · doi:10.1007/s11255-011-9991-0 · Cited by 21
Adverse safety events in patients with Chronic Kidney Disease (CKD)
Offurum, A. I., Wagner, L.-A., & Gooden, T. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1236909 · Cited by 23
“throughout the course of therapy, especially in the first 2 months and as renal function changes, and under conditions of unexpected volume depletion [22].”
BackgroundChapter 3: Blood pressure management in CKD ND patients without diabetes mellitus
(2012) · Kidney International Supplements · doi:10.1038/kisup.2012.53 · Cited by 21
Present and future of drug therapy in hypertension: an overview
Redón, J., & Carmena, R. (2024) · Blood Pressure · doi:10.1080/08037051.2024.2320401 · Cited by 27
“They slow the decline in the estimated glomerular filtration rate, reduce proteinuria and delay progression to advanced chronic kidney disease [20–22].”
Ono, T., Sanai, T., Miyahara, Y., & Noda, R. (2013) · Current Therapeutic Research · doi:10.1016/j.curtheres.2013.02.002 · Cited by 20
Valika, A. A., & Gheorghiade, M. (2012) · Heart Failure Reviews · doi:10.1007/s10741-011-9295-6 · Cited by 21
Jackevicius, C. A., Wong, J. S. W., Aroustamian, I., Gee, M., & Mody, F. V. (2014) · BMJ Open · doi:10.1136/bmjopen-2014-005181 · Cited by 23
“The use of ACEI is warranted in this group of patients, along with close monitoring of renal function and electrolytes since benefits were documented in this study as well as in previous studies.(11) 12 17–20 Limitations of our study include its retrospective study design with potential for confounding.”
ResultCombination of ACE inhibitor with nicorandil provides further protection in chronic kidney disease
Shiraishi, T., Tamura, Y., Taniguchi, K., Higaki, M., Ueda, S., Shima, T., Nagura, M., Nakagawa, T., Johnson, R. J., & Uchida, S. (2014) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00521.2014 · Cited by 21
“RAS inhibition also provides more protection in patients with mild renal dysfunction with less protection in advanced stage of renal disease (1, 12, 25, 36).”
BackgroundAccess to Enantio-enriched Substituted α-Trifluoromethyl Azepanes from l -Proline
Masson, G., Rioton, S., Pardo, D. G., & Cossy, J. (2018) · Organic Letters · doi:10.1021/acs.orglett.8b02167 · Cited by 20
Fekih, R. E., Yannoutsos, A., Blacher, J., London, G. M., & Safar, M. E. (2015) · Journal of Hypertension · doi:10.1097/hjh.0000000000000711 · Cited by 22
Adarkwah, C. C., Gandjour, A., Akkerman, M. K., & Evers, S. (2013) · Kidney & Blood Pressure Research · doi:10.1159/000350142 · Cited by 20
Expert consensus on management of diabetic patients with impairment of renal function
Bonnet, F., Gauthier, E., Gin, H., Hadjadj, S., Halimi, J.-M., Hannedouche, T. P., Rigalleau, V., Romand, D., Roussel, R., & Zaoui, P. (2011) · Diabetes & Metabolism · doi:10.1016/s1262-3636(11)70961-2 · Cited by 23
Blood Pressure Targets for Patients with Diabetes or Kidney Disease
Flynn, C. A., & Bakris, G. L. (2011) · Current Hypertension Reports · doi:10.1007/s11906-011-0228-5 · Cited by 21
Pharmacologic Management of Chronic Reno-Cardiac Syndrome
Hawwa, N., Schreiber, M. J., & Tang, W. H. W. (2012) · Current Heart Failure Reports · doi:10.1007/s11897-012-0122-8 · Cited by 20
“In the setting of RCS, a study looking at patients with CKD demonstrated consistent mortality risk reduction with benazepril, although its impact on myocardial structure and function is unclear [63].”
Polychronopoulou, E., Wuerzner, G., & Burnier, M. (2021) · Vascular Health and Risk Management · doi:10.2147/vhrm.s292522 · Cited by 26
Personalizing heart failure management in chronic kidney disease patients
Banerjee, D., & Wang, A. Y.-M. (2021) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfab026 · Cited by 22
Progression of renal disease—can we forget about inhibition of the renin–angiotensin system?
Mann, J. F. E., McClellan, W. M., Kunz, R., & Ritz, E. (2006) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfl315 · Cited by 19
“RAS inhibition slowed down the progression even in advanced renal insufficiency [15] and failed to consider information that the degree of renoprotection depends on the intensity of RAS blockade [16].”
BackgroundSerotonin regulation of mitochondria in kidney diseases
Hurtado, K. A., Scholpa, N. E., Schnellmann, J. G., & Schnellmann, R. G. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107154 · Cited by 22
Metadata
- Authors
- Hou, F. F., Zhang, X., Zhang, G. H., Xie, D., Chen, P. Y., Zhang, W. R., Jiang, J. P., Liang, M., Wang, G. B., Liu, Z. R., & Geng, R. W.
- Affiliations
- Nanfang Hospital (CN)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-01-12
- Volume
- 354
- Issue
- 2
- Pages
- 131-140
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2063210769
- Cited by
- 710
- References
- 22
- Citations by year
- 2026: 22 · 2025: 37 · 2024: 31 · 2023: 42 · 2022: 42 · 2021: 43 · 2020: 31 · 2019: 43 · 2018: 28 · 2017: 23 · 2016: 29 · 2015: 24 · 2014: 39 · 2013: 30 · 2012: 39
- FWCI
- 31.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- benazepril, ACE inhibitors, end-stage renal disease, renal protection, proteinuria, renal function decline, serum creatinine doubling, non-diabetic patients, adverse events
- MeSH terms
- Adult, Aged, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Benzazepines, Blood Pressure, China, Creatinine, Double-Blind Method, Female, Humans, Kidney Failure, Chronic, Male, Middle Aged, Proteinuria, Disease Progression, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.